News

Grifols, a global healthcare company, has launched the “Look into Genetic COPD” educational campaign to raise awareness of chronic obstructive pulmonary disease (COPD) that is caused by alpha-1-antitrypsin deficiency (alpha-1), a rare genetic condition. The global healthcare company, headquartered…

Rheumatoid arthritis (RA) patients with comorbidities like chronic obstructive pulmonary disease (COPD) or asthma are struggling to manage their respiratory condition because their inhalers are too complex, researchers at England’s University of Bath reported. The study, “Physical ability of people with rheumatoid arthritis and age-sex matched controls to…

Novartis’ Ultibro Breezhaler provided noteworthy improvements in cardiac and lung function in chronic obstructive pulmonary disease (COPD) patients with lung hyperinflation (overinflated lungs) when compared to placebo, a new research study found. The study reporting the findings, “Effect of lung deflation with indacaterol plus glycopyrronium on ventricular…

The antibiotic dirithromycin (no longer available in the U.S.; sold in other countries under the brand name Dynabac) may be a potentially effective therapy for acute exacerbations in patients with chronic obstructive pulmonary disease (COPD), according to findings from a meta-analysis of antibiotics in clinical trials. Chinese researchers published…

GSK and Innoviva submitted new Phase 3 data to support label expansion of Trelegy Ellipta for European patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are at risk of an exacerbation and require triple therapy. The regulatory submission to the…

Using long-term inhaled corticosteroids to relieve inflammation in chronic obstructive pulmonary disease (COPD) could increase the risk of bone fractures, new research suggests. A study published in the journal CHEST, “Long-term Use of Inhaled Corticosteroids in COPD and the Risk of Fracture,” was conducted by researchers from McGill University…

COPD increases the risk of a person having additional health conditions and taking multiple medications, a British study shows. The research, “Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study,” was published in the journal…

Vitamin D levels are associated with respiratory function and health, research from Australia shows. The findings suggest an additional process could be driving diseases such as chronic obstructive respiratory disease (COPD). The study, “Vitamin D and respiratory health in the Busselton Healthy Ageing Study,” was published…

The U.S. Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) submitted by Theravance Biopharma and Mylan for their collaborative compound revefenacin (TD-4208), a bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD) in adults. The two pharmaceutical companies are aiming to develop and…

AstraZeneca’s Daliresp (roflumilast) is now approved at 250 micrograms (mcg) for the first four weeks followed by 500 mcg thereafter to treat patients with chronic obstructive pulmonary disease (COPD). This approval by the U.S. Food and Drug Administration (FDA) will help reduce the rate of discontinuation previously reported in patients…